Although opioids remain indispensable for pain relief in patients with advanced cancer, their use frequently results in OIC, which can substantially reduce quality of life and, in some cases, compromise the continuation of optimal pain management. Naldemedine, a peripherally acting μ-opioid receptor antagonist, is used to treat OIC by preserving physiological bowel motility without interfering with central analgesia.
from Medical Xpress - latest medical and health news stories https://ift.tt/0uJqfBS
